Monday 06 Jul, 2020 06:43 AM
Site map | Locate Us | Login
   Sobha reports Q1 operational performance update     PVR board to meet on 6 July    National Fertilizers posts record fertilizer sale of 12.85 LMT in Q1    L&T Finance says deal to sell L&T Capital Markets (Middle East) terminated    Adani Ports records throughput of 41.5 MMT in Q1    HOEC temporarily suspends operations at PY-1 field    NLC India, Coal India form JV to develop 5,000 MW solar, thermal power assets    Marico remains cautiously optimistic amid volatile biz environment    Gati records Q4 net loss of Rs 63 cr    Indiabulls Housing Q4 PAT slump 86% to Rs 137 cr    Shriram Transport is planning to raise funds    NLC India firms up on raising Rs 500 cr via commercial papers    Omaxe Ltd leads losers in 'A' group    Edelweiss Financial gains on buzz NBFC arm sells sticky loans to global funds    Archidply Industries Ltd leads losers in 'B' group 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Divis Labs Q4 PAT climbs 33% to Rs 388 cr
06-Jun-20   15:57 Hrs IST

Consolidated profit before tax (PBT) soared 13.54% to Rs 470.96 crore in Q4 March 2020 as against Rs 414.77 crore in Q4 March 2019. Current tax expenses tanked 52.16% to Rs 53.88 crore in Q4 March 2020 as against Rs 112.63 crore in Q4 March 2019. The Q4 earnings were announced on Saturday, 6 June 2020.

Divis Laboratories has undergone 4 regulatory inspections/audits during FY20 at both its manufacturing plants. Three were conducted by the United States Food & Drug Administration (USFDA) and one was undertaken by European Directorate, European Medicines Agency (EMA).

It was reported in the previous financial year that the pharmaceutical major would be taking up two brownfield projects with an aggregate investment of Rs 1,200 crore. During the year, Divis Laboratories has capitalized assets worth Rs 876 crore for the new projects as well as for expansion at the existing facilities; and an amount of Rs 920 crore is carried forward as Capital Work-in-Progress at the end of the year. The company commenced commercial production partially during February 2020 from DC-SEZ unit. It has also commenced commercial production partially during March 2020 from DCV-SEZ unit.

Besides the brownfield projects, Divis Laboratories has taken up debottlenecking & backward integration programs at Unit-I and Unit-II facilities by investing an aggregate amount of Rs 300 crore. In addition, a project for augmentation of effluent treatment infrastructure at Unit-II facility has been taken up at an estimated cost of Rs 190 crore. However, there has been some delay in implementing the large capex projects taken by the company due to torrential rains and COVID-19 which impacted movement of people and goods.

Shares of Divis Laboratories gained 1.64% to Rs 2,460.45 on Friday, 5 June 2020. The stock is up 7.75% in a month.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.G Anand , anand@ssplwealth.com
Hit Count : 14360056
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016  |  MCX : INZ000081736
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 12815 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. Saravana Stocks Pvt. Ltd